about
An overview of long non-coding RNAs in ovarian cancersTargeted immune therapy of ovarian cancerMolecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.Frequent downregulation of miR-34 family in human ovarian cancers.Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerImmunity and immune suppression in human ovarian cancer.MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cellsPlakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer modelMicroRNA and ovarian cancer.Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.Molecularly targeted therapies for p53-mutant cancers.miRNAs and ovarian cancer: An overview.Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.Haemoglobin in pelvic fluid rescues Fallopian tube epithelial cells from reactive oxygen species stress and apoptosis.CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.A computational framework for complex disease stratification from multiple large-scale datasets.Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
P2860
Q26753467-C21943C1-8EA4-4EA7-94CD-835183172518Q28082828-4CC88A4B-AF89-4EEF-9848-D16BDCAA1567Q30430198-528F3A40-1A5E-4FC8-B699-BA48738EEEA7Q33658229-B19D5A2A-A468-420C-9871-77B24EF8B2FFQ34397197-7E58D7B4-025C-4CA0-BFC2-7F9123562402Q35138135-B8AE11D1-0925-4756-86DE-2A008B2FE120Q35694610-1A2BBC9D-F9B8-41C7-B8DB-A730B53A95FFQ36265840-997D24E3-360F-4728-8009-953AB45D327DQ36868797-DBE081C1-3CEE-4CDB-9E3B-4E50A86B0B9FQ36916354-94D2B615-6D41-421C-9107-1C966F1B03EAQ37127836-BF5B2302-801F-4886-9066-EBA4D807142FQ37200677-A8CAE0A4-6024-47E8-AC55-281CC1445A08Q37967486-31EA2A9E-CCEA-486E-8A44-8805984D989CQ38723863-88E34063-F1A2-40ED-B6F2-2074E9417238Q38949147-A7148E06-C06A-4994-BAA4-07DAC7EF315CQ39393193-FA3B7F9D-BFF9-4B79-BECE-65CE9DEF9DB4Q39432311-7A8A1012-D346-4C0D-90D3-62D6AB706AFAQ39588369-5556D048-F8FD-48B8-8912-9F03C14E8960Q46469350-7F6E95E4-BA85-4D3B-8D56-4C235F37ED83Q52592862-FE67A47D-5E88-4F36-8841-DE0F934E1B9CQ55139050-F76428FA-E148-4608-A1F8-F689C18F2DB2Q58623046-CF774079-365C-4549-AB68-2AD09BE4C559
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of p53 and Rb in ovarian cancer.
@en
Role of p53 and Rb in ovarian cancer.
@nl
type
label
Role of p53 and Rb in ovarian cancer.
@en
Role of p53 and Rb in ovarian cancer.
@nl
prefLabel
Role of p53 and Rb in ovarian cancer.
@en
Role of p53 and Rb in ovarian cancer.
@nl
P2093
P2860
P1476
Role of p53 and Rb in ovarian cancer.
@en
P2093
Alexander Yu Nikitin
Andrea Flesken-Nikitin
David C Corney
Jinhyang Choi
P2860
P304
P356
10.1007/978-0-387-68969-2_9
P407
P577
2008-01-01T00:00:00Z